{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:26Z","timestamp":1791313286552,"version":"4.3.1"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Eravacycline (formerly TP-434) was evaluated\n in vitro<\/jats:italic>\n against pre-established biofilms formed by a uropathogenic\n Escherichia coli<\/jats:named-content>\n strain. Biofilms were eradicated by 0.5 \u03bcg\/ml eravacycline, which was within 2-fold of the MIC for planktonic cells. In contrast, colistin and meropenem disrupted biofilms at 32 and 2 \u03bcg\/ml, respectively, concentrations well above their respective MICs of 0.5 and 0.03 \u03bcg\/ml. Gentamicin and levofloxacin eradicated biofilms at concentrations within 2-fold of their MICs.\n <\/jats:p>","DOI":"10.1128\/aac.04967-14","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T02:49:35Z","timestamp":1422326975000},"page":"2446-2449","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Eravacycline (TP-434) Is Active\n In Vitro<\/i>\n against Biofilms Formed by Uropathogenic Escherichia coli"],"prefix":"10.1128","volume":"59","author":[{"given":"Trudy H.","family":"Grossman","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn O.","family":"Kerstein","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2004.11.010"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI20365"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00645-13"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1318"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.2.167-193.2002"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00014-10"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2009.01323.x"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1084550"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.999-1007.2001"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1097(03)00856-5"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_1_13_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. CLSI, Wayne, PA.","edition":"9"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00650-12"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00720-06"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1641"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2458-2461.2002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04967-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04967-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:04:54Z","timestamp":1645484694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04967-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1128\/AAC.04967-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04967-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"2014-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}